Comparative performance of the SavvyCheck vaginal yeast test versus culture

NCT ID NCT05079711

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 ยท Last updated Sep 10, 2026

Summary

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women, aged 18 years and older, symptomatic and asymptomatic for vaginitis will be enrolled in the study. We estimate that it will require a total enrollment of up to 600 symptomatic women at all clinical sites combined, to achieve the target of at least n=216 Reference Method (vaginal Candida yeast culture) positives. In addition, a combined total of 320 asymptomatic women will be enrolled in the study from the four clinical sites combined, to achieve the target of at least n=170 Reference Method (vaginal Candida yeast culture) negatives.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Symptomatic Women Symptomatic women include those women who present with a complaint consistent with symptoms of vaginitis (e.g., increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination). Enrollment will continue at each clinical site until our target number of 216 Reference Method (vaginal Candida yeast culture) positives have been collected. We estimate up to 600 symptomatic women will be enrolled to meet our target. Inclusion Criteria for Symptomatic Women 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Women experiencing vaginal symptoms, including: increased discharge, itching, soreness and irritation, rash on the labia, and genital burning that may worsen during urination 7. Must determine the test is applicable to her based on her symptoms after she has read the outside device labeling (box label) Asymptomatic Women Asymptomatic women include those women who do not present with a complaint consistent with vaginitis. Enrollment will continue at each clinical site until our target number of 170 Reference Method (vaginal Candida yeast culture) negatives have been collected. We estimate up to 320 asymptomatic women will be enrolled to meet our target. Inclusion Criteria for Asymptomatic Women: 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Healthy women appearing for routine care without symptoms of vaginal yeast infection Exclusion Criteria: If any of the following criteria are met, a potential subject will be excluded from the study: 1. Currently menstruating 2. History of any clinical therapies and/or interventions related to gender confirmation (transgender person) 3. Use of any vaginal medication, taken by mouth or vaginally, within the last 7 days 4. Use of any vaginal product within 24 hours, including contraception (cream, gel, or foam), or douching solutions NOTE: Women who currently have an intrauterine device (IUD) placed are eligible to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vulvovaginal candidiasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brooke Army Medical Center

    Fort Sam Houston, Texas, 78234, United States

  • Landstuhl Regional Medical Center

    Landstuhl, Germany

  • Womack Army Medical Center

    Fort Bragg, North Carolina, 28310, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.